| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human Integrin Alpha 4/ITGA4 recombinant protein (Position: N35-V269) was used as the immunogen for the ITGA4 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
ITGA4 Antibody / Integrin Alpha 4 is a anti-ITGA4 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), ELISA with listed reactivity in Human.
Key elements and design rationale
- Target: ITGA4
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ELISA
Biological background
Integrin alpha-4 is a transmembrane glycoprotein composed of a large extracellular domain, a single transmembrane helix, and a short cytoplasmic tail that links to cytoskeletal and signaling molecules. It facilitates rolling and firm adhesion of lymphocytes and monocytes during inflammatory responses, guiding immune cells to sites of tissue injury or infection. In the nervous system, it contributes to axonal guidance and glial cell adhesion.
The ITGA4 antibody is widely used in immunology, oncology, and vascular biology research to study adhesion, immune cell migration, and integrin-mediated signaling. Flow cytometry and western blot analyses identify Integrin alpha-4 as a 150 kilodalton band, while immunohistochemistry reveals membrane staining on leukocytes, endothelium, and fibroblasts. This antibody provides a means to examine integrin expression dynamics and cell adhesion regulation under physiological and pathological conditions.
Integrin alpha-4 is clinically relevant as a therapeutic target in multiple sclerosis and Crohn's disease, where monoclonal antibodies blocking alpha4-integrin (e.g., natalizumab) reduce leukocyte infiltration and inflammation. Aberrant expression also contributes to cancer metastasis and fibrotic diseases by enhancing cell adhesion and migration. The ITGA4 antibody supports investigations into these mechanisms by detecting endogenous protein in tissues and cell lines.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
